WallStreetZenWallStreetZen

NASDAQ: AUTL
Autolus Therapeutics PLC Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

AUTL past revenue growth

How has AUTL's revenue growth performed historically?
Company
236.15%
Industry
69.78%
Market
14.1%
AUTL's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
AUTL's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
AUTL's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

AUTL earnings and revenue history

Current Revenue
$7.5M
Current Earnings
-$151.6M
Current Profit Margin
-2,025%

AUTL Return on Equity

Current Company
-64.4%
Current Industry
-18%
Current Market
30.8%
AUTL's Return on Equity (-64.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when AUTL announces earnings.

AUTL Return on Assets

Current Company
-39.7%
Current Industry
0.9%
AUTL is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

AUTL Return on Capital Employed

Current Company
-38.61%
Current Industry
14.1%
AUTL has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

AUTL vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
AUTL$7.49M-$155.02M-$151.59M+25.58%N/A
PHAT$0.00-$160.47M-$194.87MN/AN/A
TNYA$0.00-$114.05M-$124.35MN/AN/A
LXRX$126.00k-$105.48M-$110.40M-73.63%N/A
AMRN$360.54M-$88.87M-$90.70M+13.62%N/A
View Top Biotech Stocks

Autolus Therapeutics Earnings & Revenue FAQ

What were AUTL's earnings last quarter?

On Invalid Date, Autolus Therapeutics (NASDAQ: AUTL) reported Q1 2023 earnings per share (EPS) of -$0.23, up 43.9% year over year. Total Autolus Therapeutics earnings for the quarter were -$39.81 million. In the same quarter last year, Autolus Therapeutics's earnings per share (EPS) was -$0.41.

If you're new to stock investing, here's how to buy Autolus Therapeutics stock.

What was AUTL's earnings growth in the past year?

As of Q2 2023, Autolus Therapeutics's earnings has grown year over year. Autolus Therapeutics's earnings in the past year totalled -$151.59 million.

What was AUTL's revenue last quarter?

On Invalid Date, Autolus Therapeutics (NASDAQ: AUTL) reported Q1 2023 revenue of $1.29 million up 678.31% year over year. In the same quarter last year, Autolus Therapeutics's revenue was $166.00 thousand.

What was AUTL's revenue growth in the past year?

As of Q2 2023, Autolus Therapeutics's revenue has grown 236.15% year over year. This is 166.37 percentage points higher than the US Biotechnology industry revenue growth rate of 69.78%. Autolus Therapeutics's revenue in the past year totalled $7.49 million.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.